Literature DB >> 22852836

Chemical modification study of antisense gapmers.

Robert Stanton1, Simone Sciabola, Christopher Salatto, Yan Weng, Debra Moshinsky, Jeremy Little, Evan Walters, John Kreeger, Debra DiMattia, Tracy Chen, Tracey Clark, Mei Liu, Jessie Qian, Marc Roy, Robert Dullea.   

Abstract

A series of insertion patterns for chemically modified nucleotides [2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), methoxyethyl (MOE), locked nucleic acid (LNA), and G-Clamp] within antisense gapmers is studied in vitro and in vivo in the context of the glucocorticoid receptor. Correlation between lipid transfection and unassisted (gymnotic--using no transfection agent) in vitro assays is seen to be dependent on the chemical modification, with the in vivo results corresponding to the unassisted assay in vitro. While in vitro mRNA knockdown assays are typically reasonable predictors of in vivo results, G-Clamp modified antisense oligonucleotides have poor in vivo mRNA knockdown as compared to transfected cell based assays. For LNA gapmers, knockdown is seen to be highly sensitive to the length of the antisense and number of LNA insertions, with longer 5LNA-10DNA-5LNA compounds giving less activity than 3LNA-10DNA-3LNA derivatives. Additionally, the degree of hepatoxicity for antisense gapmers with identical sequences was seen to vary widely with only subtle changes in the chemical modification pattern. While the optimization of knockdown and hepatic effects remains a sequence specific exercise, general trends emerge around preferred physical properties and modification patterns.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22852836     DOI: 10.1089/nat.2012.0366

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  43 in total

Review 1.  Therapeutic targeting of microRNAs: current status and future challenges.

Authors:  Zhonghan Li; Tariq M Rana
Journal:  Nat Rev Drug Discov       Date:  2014-07-11       Impact factor: 84.694

2.  Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.

Authors:  Tsuyoshi Yamamoto; Naoko Fujii; Hidenori Yasuhara; Shunsuke Wada; Fumito Wada; Naoya Shigesada; Mariko Harada-Shiba; Satoshi Obika
Journal:  Nucleic Acid Ther       Date:  2014-04-23       Impact factor: 5.486

Review 3.  Therapeutic nucleic acids: current clinical status.

Authors:  Kannan Sridharan; Nithya Jaideep Gogtay
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

4.  Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern.

Authors:  Peter H Hagedorn; Victor Yakimov; Søren Ottosen; Susanne Kammler; Niels F Nielsen; Anja M Høg; Maj Hedtjärn; Michael Meldgaard; Marianne R Møller; Henrik Orum; Troels Koch; Morten Lindow
Journal:  Nucleic Acid Ther       Date:  2013-08-16       Impact factor: 5.486

Review 5.  HDL and microRNA therapeutics in cardiovascular disease.

Authors:  Danielle L Michell; Kasey C Vickers
Journal:  Pharmacol Ther       Date:  2016-09-03       Impact factor: 12.310

6.  Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.

Authors:  Daniela Castanotto; Min Lin; Claudia Kowolik; Troels Koch; Bo Rode Hansen; Henrik Oerum; Cy A Stein
Journal:  Mol Ther       Date:  2016-03-10       Impact factor: 11.454

7.  Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics.

Authors:  Kirsten Deprey; Nefeli Batistatou; Marjoke F Debets; Jack Godfrey; Kirstin B VanderWall; Rebecca R Miles; Livia Shehaj; Jiaxing Guo; Amy Andreucci; Pachamuthu Kandasamy; Genliang Lu; Mamoru Shimizu; Chandra Vargeese; Joshua A Kritzer
Journal:  ACS Chem Biol       Date:  2022-01-15       Impact factor: 4.634

8.  Quantum mechanical studies of DNA and LNA.

Authors:  Troels Koch; Irene Shim; Morten Lindow; Henrik Ørum; Henrik G Bohr
Journal:  Nucleic Acid Ther       Date:  2014-02-03       Impact factor: 5.486

9.  Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.

Authors:  Kim A Lennox; Richard Owczarzy; Derek M Thomas; Joseph A Walder; Mark A Behlke
Journal:  Mol Ther Nucleic Acids       Date:  2013-08-27       Impact factor: 10.183

10.  Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip.

Authors:  Tom T G Nieskens; Otto Magnusson; Patrik Andersson; Magnus Söderberg; Mikael Persson; Anna-Karin Sjögren
Journal:  Arch Toxicol       Date:  2021-05-07       Impact factor: 6.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.